http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-104945498-B
Outgoing Links
| Predicate | Object |
|---|---|
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K1-107 |
| filingDate | 2014-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2018-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2018-08-03-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-104945498-B |
| titleOfInvention | The preparation of long-actingization PEG-rExendin-4 modifier conjugates |
| abstract | The invention discloses coupled product preparation processes made of 4 modifiers of genetic recombination Exendin and Y types maleimide (Y MAL 40K) polyethylene glycol conjugation, compared to the rExendin 4 without PEG coupling modifications, plasma half-life is obviously prolonged in human body, conjugate preferably remains 4 biological activities of rExendin, reach reduction times for spraying, immunogenicity effect is reduced, the long lasting drug formulations for the treatment of type-2 diabetes mellitus can be developed into. |
| priorityDate | 2014-03-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 115.